RE:RE:RE:RE:RE:RE:June presentation The share price went from 38 cents to now by moving the goal posts by 8 weeks and not showing a single material development on the list. We want him to communicate with us but we don't want any more information other than a material announcement. So his strategy was to do an interview.
I believe the second trial on healthy subjects produced an unexpected benefit correlated to varying doses of the sglt2 tablets and hence another phase 1 launched. That could be why we didn't hear phase 1 original clinical when we should. The most plausible to me is the healthy subjects had sizeable weight loss with no side effects, which if true could be highly interesting. Wouldn't be surprised if that is a trillion dollar market by now. But of course when do we find out with material facts what it could be?